Lacosamide is NOT Recommended for Osteoarthritis
Lacosamide has no established role in osteoarthritis treatment and is not mentioned in any major OA clinical practice guidelines. This medication is FDA-approved as an anticonvulsant for epilepsy, not for pain management in osteoarthritis 1.
Why This Matters
The most authoritative and recent guidelines for OA management—including the 2019 ACR/Arthritis Foundation guideline 2 and the 2018 EULAR recommendations 3—make no mention of lacosamide whatsoever. These comprehensive guidelines evaluated extensive evidence for multiple treatment modalities and provided clear recommendations for what should and should not be used in OA. The complete absence of lacosamide from these guidelines indicates it has not met the threshold for clinical consideration in OA treatment.
What the Guidelines Actually Recommend
For OA pain management, evidence-based options include 2:
Strong recommendations:
- Oral and topical NSAIDs
- Intraarticular glucocorticoid injections (knee)
- Exercise and weight loss
Conditional recommendations:
- Duloxetine
- Tramadol
- Topical capsaicin
- Acetaminophen
The Preclinical Research Context
While animal studies show lacosamide reduced pain behaviors in rat OA models 4, 5, and very recent 2026 research explored hydrogel delivery systems 6, these are exclusively preclinical investigations with no human clinical trial data for OA. The gap between promising animal models and clinical efficacy is substantial—many compounds that work in rodent arthritis models fail in human trials.
Clinical Bottom Line
Use established, guideline-recommended therapies for OA pain. Lacosamide remains an investigational concept for OA without human efficacy or safety data in this population. Prescribing it off-label for OA would be inappropriate given the availability of evidence-based alternatives with known benefit-risk profiles in OA patients 7, 8, 9.